Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 184

1.

Inherited susceptibility to lung cancer may be associated with the T790M drug resistance mutation in EGFR.

Bell DW, Gore I, Okimoto RA, Godin-Heymann N, Sordella R, Mulloy R, Sharma SV, Brannigan BW, Mohapatra G, Settleman J, Haber DA.

Nat Genet. 2005 Dec;37(12):1315-6. Epub 2005 Oct 30.

PMID:
16258541
2.

Drugging the bad "AKT-TOR" to overcome TKI-resistant lung cancer.

Settleman J, Kurie JM.

Cancer Cell. 2007 Jul;12(1):6-8. Review.

3.

Searching for a magic bullet in NSCLC: the role of epidermal growth factor receptor mutations and tyrosine kinase inhibitors.

Wong KK.

Lung Cancer. 2008 Jun;60 Suppl 2:S10-8. doi: 10.1016/S0169-5002(08)70100-4. Review.

PMID:
18513579
4.

Comparison of epidermal growth factor receptor mutations between primary and corresponding metastatic tumors in tyrosine kinase inhibitor-naive non-small-cell lung cancer.

Gow CH, Chang YL, Hsu YC, Tsai MF, Wu CT, Yu CJ, Yang CH, Lee YC, Yang PC, Shih JY.

Ann Oncol. 2009 Apr;20(4):696-702. doi: 10.1093/annonc/mdn679. Epub 2008 Dec 16.

5.

Detection of low-level EGFR T790M mutation in lung cancer tissues.

Oh JE, An CH, Yoo NJ, Lee SH.

APMIS. 2011 Jul;119(7):403-11. doi: 10.1111/j.1600-0463.2011.02738.x. Epub 2011 May 14.

PMID:
21635547
6.

Analysis of epidermal growth factor receptor gene mutation in patients with non-small cell lung cancer and acquired resistance to gefitinib.

Kosaka T, Yatabe Y, Endoh H, Yoshida K, Hida T, Tsuboi M, Tada H, Kuwano H, Mitsudomi T.

Clin Cancer Res. 2006 Oct 1;12(19):5764-9.

7.

[Overcoming resistance to EGFR-TKI in lung cancer].

Takeda K.

Gan To Kagaku Ryoho. 2009 Apr;36(4):552-6. Japanese.

PMID:
19381026
8.

Chemogenomic profiling provides insights into the limited activity of irreversible EGFR Inhibitors in tumor cells expressing the T790M EGFR resistance mutation.

Sos ML, Rode HB, Heynck S, Peifer M, Fischer F, Klüter S, Pawar VG, Reuter C, Heuckmann JM, Weiss J, Ruddigkeit L, Rabiller M, Koker M, Simard JR, Getlik M, Yuza Y, Chen TH, Greulich H, Thomas RK, Rauh D.

Cancer Res. 2010 Feb 1;70(3):868-74. doi: 10.1158/0008-5472.CAN-09-3106. Epub 2010 Jan 26.

10.

Epidermal growth factor receptor mutations in lung cancer.

Sharma SV, Bell DW, Settleman J, Haber DA.

Nat Rev Cancer. 2007 Mar;7(3):169-81. Review.

PMID:
17318210
12.

ALK, lung cancer, and personalized therapy: portent of the future?

Garber K.

J Natl Cancer Inst. 2010 May 19;102(10):672-5. doi: 10.1093/jnci/djq184. Epub 2010 May 11. No abstract available.

13.

Rebiopsy of non-small cell lung cancer patients with acquired resistance to epidermal growth factor receptor-tyrosine kinase inhibitor: Comparison between T790M mutation-positive and mutation-negative populations.

Hata A, Katakami N, Yoshioka H, Takeshita J, Tanaka K, Nanjo S, Fujita S, Kaji R, Imai Y, Monden K, Matsumoto T, Nagata K, Otsuka K, Tachikawa R, Tomii K, Kunimasa K, Iwasaku M, Nishiyama A, Ishida T, Nishimura Y.

Cancer. 2013 Dec 15;119(24):4325-32. doi: 10.1002/cncr.28364. Epub 2013 Sep 16.

14.

Highly sensitive and noninvasive detection of epidermal growth factor receptor T790M mutation in non-small cell lung cancer.

He C, Zheng L, Xu Y, Liu M, Li Y, Xu J.

Clin Chim Acta. 2013 Oct 21;425:119-24. doi: 10.1016/j.cca.2013.07.012. Epub 2013 Jul 23.

PMID:
23886554
15.

Effect of siRNAs targeting the EGFR T790M mutation in a non-small cell lung cancer cell line resistant to EGFR tyrosine kinase inhibitors and combination with various agents.

Chen G, Kronenberger P, Teugels E, Umelo IA, De Grève J.

Biochem Biophys Res Commun. 2013 Feb 15;431(3):623-9. doi: 10.1016/j.bbrc.2012.12.070. Epub 2012 Dec 22.

PMID:
23266614
16.

Epidermal growth factor receptor tyrosine kinase inhibitors in lung cancer: impact of primary or secondary mutations.

Sakurada A, Shepherd FA, Tsao MS.

Clin Lung Cancer. 2006 May;7 Suppl 4:S138-44. Review.

PMID:
16764754
17.

Selecting patients for treatment with epidermal growth factor tyrosine kinase inhibitors.

Bonomi PD, Buckingham L, Coon J.

Clin Cancer Res. 2007 Aug 1;13(15 Pt 2):s4606-12. Review.

18.

Resistance to an irreversible epidermal growth factor receptor (EGFR) inhibitor in EGFR-mutant lung cancer reveals novel treatment strategies.

Yu Z, Boggon TJ, Kobayashi S, Jin C, Ma PC, Dowlati A, Kern JA, Tenen DG, Halmos B.

Cancer Res. 2007 Nov 1;67(21):10417-27.

19.

Epidermal growth factor receptor in relation to tumor development: EGFR gene and cancer.

Mitsudomi T, Yatabe Y.

FEBS J. 2010 Jan;277(2):301-8. doi: 10.1111/j.1742-4658.2009.07448.x. Epub 2009 Nov 18. Review.

Items per page

Supplemental Content

Write to the Help Desk